BEAM
Beam Therapeutics IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$3.10B
P/E Ratio
—
EPS
$-0.49
Beta
2.20
52W High
$36.44
52W Low
$15.60
50-Day MA
$29.47
200-Day MA
$26.62
Dividend Yield
—
Profit Margin
-40.20%
Forward P/E
—
PEG Ratio
—
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, develops precision genetic drugs for patients with serious illnesses in the United States. The company is headquartered in Cambridge, Massachusetts.
Fundamentals
| Revenue (TTM) | $164.01M |
| Gross Profit (TTM) | $-240.93M |
| EBITDA | $-349.25M |
| Operating Margin | -337.80% |
| Return on Equity | -5.77% |
| Return on Assets | -15.80% |
| Revenue/Share (TTM) | $1.60 |
| Book Value | $11.71 |
| Price-to-Book | 2.60 |
| Price-to-Sales (TTM) | 18.92 |
| EV/Revenue | 12.59 |
| EV/EBITDA | -7.03 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | 324.90% |
| Shares Outstanding | $102.88M |
| Float | $87.97M |
| % Insiders | 1.36% |
| % Institutions | 107.03% |
Historical Volatility
HV 10-Day
95.44%
HV 20-Day
80.34%
HV 30-Day
78.56%
HV 60-Day
74.02%
HV Rank
69.4%
Volatility is currently expanding
Analyst Ratings
Consensus ($51.07 target)
1
Strong Buy14
Buy2
HoldMore HEALTHCARE Stocks
Data last updated: 6/13/2026